DNA 修復药物市场按药物类型、用途、给药途径、分销管道和地区划分

2025 年全球 DNA 修復药物市场规模估计为 80.5 亿美元，预计到 2032 年将达到 192.9 亿美元，2025 年至 2032 年的年复合成长率（CAGR）为 13.3%。

数字。 2025 年 DNA 修復药物市场占有率（按地区）

DNA修復药物旨在提高细胞识别和修復受损DNA的能力，可能用于治疗癌症和其他与基因组不稳定性相关的疾病。人体内的 DNA 会因环境暴露和其他细胞过程而自然磨损，随着时间的推移，会导致断裂和其他类型的损伤。正常情况下，细胞会透过进化优化DNA修復途径来修復此类损伤并防止突变的累积。然而，某些疾病状态与 DNA 修復缺陷有关。药理学增强 DNA 修復机制可能有助于解决未满足的需求。一些生技公司和大型製药公司正在研究针对修復途径中的关键蛋白质（如PARP、ATR、ATM和其他参与DNA损害反应的分子）的DNA修復药物。这一新兴领域有望为开发癌症和遗传疾病的精准疗法带来希望。

市场动态

全球 DNA 修復药物市场的成长是由全球癌症发生率的上升以及 DNA 损伤与各种疾病发展之间的关联在临床上的重要性日益增加所推动的。此外，增加医药研发投入以确定 DNA 修復途径中的分子标靶以及对各种候选药物进行持续的临床试验，可能会为市场参与企业提供有利可图的机会。然而，与 DNA 生物学相关的复杂性和与脱靶效应相关的安全风险可能会阻碍全面理解和临床应用。过高的开发成本也可能成为市场发展的障碍。业界正专注于生物标记策略来选择有反应的患者群体和联合治疗方法，以最大限度地提高疗效同时最大限度地降低毒性。未来的药物研发工作可能拓宽视野，不仅限于癌症。

研究的主要特点

• 本报告对全球 DNA 修復药物市场进行了详细分析，并以 2024 年为基准年，给出了预测期（2025-2032 年）的市场规模（十亿美元）和年复合成长率（CAGR%）。
• 它揭示了各个领域的潜在商机并解释了该市场的有吸引力的投资提案矩阵。
• 它还提供了对市场驱动因素、限制因素、机会、新产品发布和核准、市场趋势、区域前景以及主要企业采用的竞争策略的重要见解。
• 全球 DNA 修復药物市场的主要企业根据公司亮点、产品系列、关键亮点、财务绩效和策略等参数进行分析。
• 本报告的见解将使负责人和企业经营团队能够就未来产品发布、新兴趋势、市场扩张和行销策略做出明智的决策。
• 全球 DNA 修復药物市场报告迎合了该行业的各个相关人员，例如投资者、供应商、产品製造商、经销商、新进业者和金融分析师。
• 相关人员可以透过全球 DNA 修復剂市场分析中使用的各种策略矩阵来促进他们的决策。

目录

第一章 调查目的与前提条件

• 研究目标
• 先决条件
• 简称

第二章 市场展望

• 报告描述
  • 市场定义和范围
• 执行摘要
• 一致的机会图 (COM)

第三章市场动态、法规与趋势分析

• 市场动态
  • 驱动程式
  • 限制因素
  • 机会
• 影响分析
• 市场趋势
• 监管情景
• 收购和合作场景
• 资金筹措和投资
• PEST分析
• 波特的分析

第四章 全球 DNA 修復药物市场-冠状病毒 (COVID-19) 大流行的影响

• 整体影响
• 政府倡议
• COVID-19 市场影响

5. 2020-2032 年全球 DNA 修復药物市场（按药物类型划分）（十亿美元）

• 介绍
• 尼拉帕尼（Zejula）
• LYNPARZA（ Lynparza ）
• Rucaparib（Rubraca）
• 他拉唑帕尼（Talzenna）

6. 全球 DNA 修復药物市场，按应用划分，2020-2032 年（十亿美元）

• 介绍
• 卵巢癌
• 乳癌
• 摄护腺癌
• 肺癌
• 腹膜癌
• 其他的

7. 2020 年至 2032 年按给药途径分類的全球 DNA 修復药物市场（十亿美元）

• 介绍
• 口服
• 肠外
• 其他的

8. 2020-2032 年全球 DNA 修復药物市场按分销管道划分（十亿美元）

• 介绍
• 医院药房
• 零售药局
• 网路药局

9. 2020 年至 2032 年全球 DNA 修復药物市场（按地区划分）（十亿美元）

• 介绍
• 北美洲
• 拉丁美洲
• 欧洲
• 亚太地区
• 中东
• 非洲

第十章 竞争格局

• 公司简介
  • AstraZeneca PLC
  • Merck & Co., Inc.
  • Pfizer Inc.
  • Clovis Oncology
  • Johnson & Johnson Services, Inc.
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • GlaxoSmithKline plc（GSK）
  • Novartis AG
  • Roche Holding AG
  • Agios Pharmaceuticals, Inc.
  • AbbVie Inc.
  • Teva Pharmaceutical Industries Ltd.
  • BioMarin Pharmaceutical Inc.
  • Takeda Pharmaceutical Company Limited
  • NMS Group

第 11 章 分析师建议

• 兴衰
• 一致的机会地图

第 12 章参考文献与调查方法

• 参考
• 调查方法

Global Dna Repair Drugs Market is estimated to be valued at USD 8.05 Bn in 2025 and is expected to reach USD 19.29 Bn by 2032, growing at a compound annual growth rate (CAGR) of 13.3% from 2025 to 2032.

Figure. Dna Repair Drugs Market Share (%), By Region 2025

DNA repair drugs aim to improve the ability of cells to identify and repair damaged DNA, which could have applications in treating cancer and other diseases related to genomic instability. DNA in the human body undergoes natural wear and tear from environmental exposures and other cellular processes that can cause breaks and other types of damage over time. Under normal circumstances, cells have evolutionarily optimized DNA repair pathways to fix such lesions and prevent mutations from accumulating. However, certain medical conditions are linked to deficiencies in DNA repair capacity. Enhancing DNA repair mechanisms pharmaceutically could help address unmet clinical needs. Several biotechs and big pharmaceutical firms are researching DNA repair drugs that target key proteins in repair pathways such as PARP, ATR, ATM and other molecules involved in DNA damage response. This budding field holds promise for developing precision medicines for cancer and genetic disorders.

Market Dynamics:

Global DNA repair drugs market growth is driven by rising cancer burden worldwide and growing clinical emphasis on DNA damage links to various disease pathogenesis. Furthermore, increasing pharmaceutical R&D investments to identify molecular targets in DNA repair pathways and ongoing clinical trials for various candidates can offer lucrative opportunities for market players. However, complexities associated with DNA biology and safety risks pertaining to off-target effects can hamper complete understanding and clinical translation. High costs of development can hamper the market growth. Industry players are focused on biomarker strategies to select responder patient populations and combination therapy approaches to maximize efficacy while minimizing toxicity. Future discovery efforts can expand the scope into non-oncology areas.

Key Features of the Study:

• This report provides in-depth analysis of the global DNA repair drugs market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global DNA repair drugs market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include AbbVie, Bristol-Myers Squibb, GlaxoSmithKline, Merck, Novartis, Genentech, Pfizer, AstraZeneca
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• Global DNA repair drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global DNA repair drugs market

Detailed Segmentation-

• By Drug Type
  • Niraparib (Zejula)
  • Olaparib (Lynparza)
  • Rucaparib (Rubraca)
  • Talazoparib (Talzenna)
• By Route of Administration
  • Oral
  • Parenteral
  • Others
• By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• By Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East
  • Africa
• Company Profiles:
  • AstraZeneca PLC
  • Merck & Co., Inc.
  • Pfizer Inc.
  • Clovis Oncology
  • Johnson & Johnson Services, Inc.
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • GlaxoSmithKline plc (GSK)
  • Novartis AG
  • Roche Holding AG
  • Agios Pharmaceuticals, Inc.
  • AbbVie Inc.
  • Teva Pharmaceutical Industries Ltd.
  • BioMarin Pharmaceutical Inc.
  • Takeda Pharmaceutical Company Limited
  • NMS Group

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snapshot, By Drug Type
  • Market Snapshot, By Application
  • Market Snapshot, By Route of Administration
  • Market Snapshot, By Distribution Channel
  • Market Snapshot, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Opportunities
• Impact Analysis
• Market Trends
• Key Developments
• Regulatory Scenario
• Acquisitions and Partnerships Scenario
• Funding and Investments
• PEST Analysis
• Porter's Analysis

4. Global DNA Repair Drugs Market - Impact of Coronavirus (COVID-19) Pandemic

• Overall Impact
• Government Initiatives
• COVID-19 Impact on the Market

5. Global DNA Repair Drugs Market, By Drug Type, 2020 - 2032, (USD Bn)

• Overview
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2020 - 2032
  • Segment Trends
• Niraparib (Zejula)
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Olaparib (Lynparza)
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Rucaparib (Rubraca)
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Talazoparib (Talzenna)
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

6. Global DNA Repair Drugs Market, By Application, 2020 - 2032, (USD Bn)

• Overview
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2020 - 2032
  • Segment Trends
• Ovarian Cancer
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Breast Cancer
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Prostate Cancer
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Lung Cancer
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Peritoneal Cancer
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Others
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

7. Global DNA Repair Drugs Market, By Route of Administration, 2020 - 2032, (USD Bn)

• Overview
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2020 - 2032
  • Segment Trends
• Oral
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Parenteral
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Others
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

8. Global DNA Repair Drugs Market, By Distribution Channel, 2020 - 2032, (USD Bn)

• Overview
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2020 - 2032
  • Segment Trends
• Hospital Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Retail Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Online Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

9. Global DNA Repair Drugs Market, By Region, 2020 - 2032, (USD Bn)

• Introduction
  • Market Share Analysis, By Region, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, For Region, 2020-2032
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
    • U.S.
    • Canada
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
    • China
    • India
    • Japan
    • ASEAN
    • Australia
    • South Korea
    • Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
    • GCC Countries
    • Israel
    • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2020 - 2032, (USD Bn)
    • North Africa
    • Central Africa
    • South Africa

10. Competitive Landscape

• Company Profiles
  • AstraZeneca PLC
    • Company Highlights
    • Method Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Merck & Co., Inc.
  • Merck & Co., Inc.
  • Pfizer Inc.
  • Clovis Oncology
  • Johnson & Johnson Services, Inc.
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • GlaxoSmithKline plc (GSK)
  • Novartis AG
  • Roche Holding AG
  • Agios Pharmaceuticals, Inc.
  • AbbVie Inc.
  • Teva Pharmaceutical Industries Ltd.
  • BioMarin Pharmaceutical Inc.
  • Takeda Pharmaceutical Company Limited
  • NMS Group

11. Analyst Recommendations

• Wheel of Fortune
• Analyst View
• Coherent Opportunity Map

12. References and Research Methodology

• References
• Research Methodology
• About us and Sales Contact